Compare F5 Inc (FFIV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Twist Bioscience Corp — how do they compare? F5 Inc trades at $415.62 (market cap $23.22B), while Twist Bioscience Corp trades at $124 (market cap $7.82B). The key difference: F5 Inc is far larger — about 3× Twist Bioscience Corp's market cap. Which is the better fit depends on your goals.
| FFIV | TWST | |
|---|---|---|
Market Cap | $23.22B | $7.82B |
Sector | Technology | Health |
52-Week High | $431.26 | $124.88 |
52-Week Low | $223.99 | $24.16 |
Enterprise Value | $21.86B | $7.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $400.23, down 3.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $4.73 versus $4.00 expected, and raised its fiscal outlook, driven by 19% product revenue growth. Fundamentals show robust profitability with a net income margin of 21.95% and consistent revenue growth, though valuation ratios like a P/E of 31.89 appear elevated. Analyst sentiment is mixed with a 40% buy rating.
The outlook is cautiously optimistic given earnings momentum and raised guidance, but risks include high valuation and competitive pressures. The consensus price target of $430.43 suggests modest upside potential from current levels, contingent on sustained execution in application security and hybrid cloud demand.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
